A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity

Japanese Journal of Clinical Oncology

Volumn 37, Issue 4, 2007, Pages 245-249

  Suzuki, Minoru ^a   Sakurai, Yoshinori ^a   Masunaga, Shinichiro ^a   Kinashi, Yuko ^a   Nagata, Kenji ^a   Maruhashi, Akira ^a   Ono, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

BNCT; Experimental study; Malignant pleural mesothelioma

Indexed keywords

4 BORONOPHENYLALANINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOMA CELL; CONTROLLED STUDY; DOSIMETRY; FEMALE; INCIDENCE; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NEUTRON CAPTURE THERAPY; NONHUMAN; PLEURA MESOTHELIOMA; SQUAMOUS CELL CARCINOMA; THORACIC CAVITY;

ANIMALS; BORON NEUTRON CAPTURE THERAPY; CARCINOMA, SQUAMOUS CELL; DISEASE MODELS, ANIMAL; FEMALE; MESOTHELIOMA; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; THORACIC NEOPLASMS;

EID: 34447632875     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym022     Document Type: Article

References (14)

1. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-72.
2. Robinson BW, Musk AW, Lake R. Malignant mesothelioma. Lancet 2005;366:397-408.
3. Gordon W, Jr, Antman KH, Greenberger JS, Weichselbaum RR, Chaffey JT. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982;8:19-25.
4. Haritz D, Gabel D, Huiskamp R. Clinical phase-I study of Na2B12H11SH (BSH) in patients with malignant glioma as a precondition for boron neutron capture therapy (BNCT). Int J Radiat Oncol Biol Phys 1994;28:1175-81.
5. Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol 2003;62:101-9.
6. Fukuda H, Hiratsuka J, Kobayashi T, Sakurai Y, Yoshino K, Karashima H, et al. Boron neutron capture therapy (BNCT) for malignant melanoma with special reference to absorbed doses to the normal skin and tumor. Australas Phys Eng Sci Med 2003; 26:97-103.
7. Kato I, Ono K, Sakurai Y, Ohmae M, Maruhashi A, Imahori Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. Appl Radiat Isot 2004;61:1069-73.
8. Coderre JA, Morris GM. The radiation biology of boron neutron capture therapy. Radiat Res 1999;151:1-18.
9. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-70.
10. Kiger JL, Kiger WS, Patel H, Binns PJ, Riley KJ, Hopewell JW, et al. Effects of boron neutron capture irradiation on the normal lung of rats. Appl Radiat Isot 2004;61:969-73.
11. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of marine carcinomas. Clin Cancer Res 1999;5:2884-90.
12. Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005;10:266-283.
13. Sakurai Y, Kobayashi T. Controllability of depth dose distribution for neutron capture therapy at the Heavy Water Neutron Irradiation Facility of Kyoto University Research Reactor. Med Phys 2002;29:2338-50.
14. Suzuki M, Sakurai Y, Masunaga S, Kinashi Y, Nagata K, Maruhashi A, et al. Feasibility of boron neutron capture therapy (BNCT) for malignant pleural mesothelioma from a viewpoint of dose distribution analysis. Int J Radiat Oncol Biol Phys 2006;66:1584-9.